COLLAGEN, ECM & TISSUE-MATRIX RESEARCH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the most common questions about these two recovery and tissue-repair research peptides.
What does a GHK-Cu peptide do?
GHK-Cu does two things at once: it ferries copper into tissue and it signals matrix-making cells to rebuild their scaffolding. At picomolar-to-nanomolar concentrations it tells dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and decorin, while rebalancing the enzymes that degrade the matrix against their inhibitors [6]. The copper it carries enables cross-linking enzymes to bolt newly made collagen and elastin together, and it also shows antioxidant activity. At the gene level, it has been shown to shift expression of roughly 31.2% of human genes toward repair, protein quality-control and DNA-fidelity programs [2].
What is GHK-Cu and how does it work?
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine chelated (firmly bound) one-to-one to a copper(II) ion. The same GHK sequence occurs naturally inside type I collagen, so when the body breaks down old collagen during normal turnover, it may release this signal as a local cue for new matrix production [4][6]. The mechanism is direct fibroblast activation: GHK-Cu stimulates collagen synthesis at concentrations beginning around 10⁻¹² to 10⁻¹¹ molar, peaking around 10⁻⁹ molar, without simply increasing cell number — it changes what cells do, not how many there are [7].
Is GHK-Cu peptide really anti-aging?
There is real, if modest, topical human evidence for skin benefits. Topical GHK-Cu increased collagen production in about 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison, and reviews document placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [4]. Two caveats belong with that: the often-quoted "~4,000 genes" figure is an extrapolation; the verified number at the rigorous 50%-change threshold is approximately 2,100 genes [2]. And the peptide penetrates intact skin poorly, which caps topical delivery without delivery aids such as microneedling [1]. Systemic "anti-aging" claims have no controlled human basis.
What is the difference between GHK and GHK-Cu?
GHK is the bare tripeptide glycyl-histidyl-lysine; GHK-Cu is that same tripeptide chelated to a copper(II) ion. The distinction is not cosmetic — copper coordination is required for most of the reported bioactivities, including collagen stimulation, MMP-2 up-regulation and the antioxidant properties. The free GHK peptide without copper does not reproduce these key effects in cell studies. When research describes collagen synthesis, matrix remodeling or gene-expression shifts, it is describing the copper complex, not the bare tripeptide. The two are frequently conflated in secondary web sources [4][6].
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide. Its repair effects are tied most consistently to angiogenesis — promoting new blood-vessel growth into damaged tissue by up-regulating and internalizing the VEGFR2 receptor with downstream VEGFR2-Akt-eNOS signaling [11]. It has accelerated healing in rat models of gastric ulcers [12] and also modulates brain-gut signaling pathways and cell-migration machinery (FAK-paxillin). The critical context: almost all of this is preclinical, and human evidence is limited to three small pilot studies as of 2025 [9].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and is not growth hormone in any form. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. The potential confusion point: in tendon fibroblast studies, BPC-157 has been reported to sensitize the growth-hormone receptor, which may amplify the effect of the body's own growth hormone in that tissue context. Making a receptor more responsive is not the same as being a growth hormone. BPC-157 does not substitute for or act as growth hormone [11].
Does BPC-157 work immediately?
The intact peptide clears from the bloodstream quickly. Pharmacokinetic work in rats and dogs found an elimination half-life of under 30 minutes and rapid breakdown into small peptide fragments [10]. This means the intact molecule does not linger for long after a dose. Whether any tissue-repair effect appears immediately is a separate question not answered by the human evidence, which consists of three small pilots, and the animal healing data are measured over days to weeks, not single-dose acute outcomes [9][10]. This site does not advise on use or timing.
Does BPC-157 damage the liver?
The available data do not show liver harm, but the dataset is very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic, cardiac, renal, thyroid or glucose biomarkers and no adverse events [8]. That is reassuring, but two people in a safety pilot does not constitute a liver-safety study. The broader literature notes that without long-term, large-sample human data the overall safety profile remains genuinely unknown [9]. Nothing here is medical advice.
Can GHK-Cu and BPC-157 be used together?
This desk does not advise on use, combinations or protocols. No published controlled human study has examined GHK-Cu and BPC-157 in combination. They operate through different pathways — GHK-Cu through direct fibroblast and matrix signaling, BPC-157 through angiogenesis and cytoprotection — so there is no obvious pharmacological conflict known from the literature, but there is also no human safety or efficacy data for any combined use. Anyone considering research use of either compound should understand both are unapproved and uncharacterized in humans beyond a very small set of pilots.
Why does GHK-Cu not penetrate skin well?
The barrier is physical chemistry: the intact GHK-Cu molecule has a calculated logP (fat-versus-water partition coefficient) of approximately -2.24, making it very water-soluble and poorly oil-soluble. The outermost skin layer (stratum corneum) is a lipid-rich barrier that preferentially lets fat-soluble molecules through, so a strongly hydrophilic peptide like GHK-Cu does not cross it well on its own [1]. Strategies studied to improve penetration include palmitoylation (adding a fatty acid chain to shift the logP to ~1.14) and microneedle pretreatment, which bypassed the barrier mechanically and enabled approximately 134 nmol GHK to permeate versus essentially none through intact skin [1].
What does the research say about BPC-157 and tendon healing?
The animal evidence for BPC-157 in tendon healing is among the most cited findings in its literature. In a rat model of fully transected Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures and stimulated tendon-cell (tendocyte) outgrowth in culture, with better collagen organization and restored tendon integrity versus untreated controls. This is preclinical rodent data [12]. No controlled human trial of BPC-157 for tendon healing exists; the 2025 narrative review treats it as investigational pending rigorous human study [9]. Community reports of tendon and ligament improvements are anecdotal, not clinical evidence.
Is BPC-157 banned in sport?
Yes. BPC-157 is prohibited at all times in sport by the World Anti-Doping Agency (WADA) under the S0 category (non-approved substances). This applies to use in and out of competition, not only on competition days [9]. Any athlete subject to drug testing should treat BPC-157 as a prohibited substance and avoid it entirely. GHK-Cu is not currently specifically listed on the WADA Prohibited List as of the 2024-2025 published lists, but the S0 catch-all category can apply to non-approved pharmacological substances used by any route other than approved topical cosmetic use; athletes should verify the current Prohibited List directly.